Literature DB >> 18284361

A review of the smallpox vaccine adverse events active surveillance system.

Tracy N Thomas1, Susan Reef, Linda Neff, Mercedes M Sniadack, Gina T Mootrey.   

Abstract

In response to concern about smallpox possibly being used as a biological weapon, the President of the United States launched the National Smallpox Pre-Event Vaccination Program on 13 December 2002. Given safety concerns, identifying potentially serious adverse events (SAEs) was an essential tool of the program. To monitor for SAEs, both enhanced passive surveillance and active surveillance systems were used. The enhanced passive system was built, in part, on the existing Vaccine Adverse Event Reporting System; the active system was implemented 24 January 2003. During January 2003-May 2005, the active system detected only 1 SAE in addition to those reported through the enhanced passive system. Furthermore, the active system was not universally used by states. With the enhancements to passive surveillance, the performance of enhanced passive surveillance was comparable to that of active surveillance. However, an active surveillance system may be important when there is no enhanced passive surveillance system available.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18284361     DOI: 10.1086/524742

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  3 in total

Review 1.  Application of radiation technology in vaccines development.

Authors:  Ho Seong Seo
Journal:  Clin Exp Vaccine Res       Date:  2015-07-29

2.  Inhalational monkeypox virus infection in cynomolgus macaques.

Authors:  Roy E Barnewall; David A Fisher; Ashley B Robertson; Pauline A Vales; Katherine A Knostman; John E Bigger
Journal:  Front Cell Infect Microbiol       Date:  2012-09-17       Impact factor: 5.293

3.  Repeated high-dose (5 × 10(8) TCID50) toxicity study of a third generation smallpox vaccine (IMVAMUNE) in New Zealand white rabbits.

Authors:  Julia A Tree; Graham Hall; Peter Rees; Julia Vipond; Simon G P Funnell; Allen D Roberts
Journal:  Hum Vaccin Immunother       Date:  2016-07-02       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.